Needham & Company LLC Reiterates “Hold” Rating for Omeros (NASDAQ:OMER)

Omeros (NASDAQ:OMER)‘s stock had its “hold” rating reiterated by stock analysts at Needham & Company LLC in a research report issued to clients and investors on Friday,Benzinga reports.

Several other research firms have also weighed in on OMER. D. Boral Capital restated a “buy” rating and set a $36.00 target price on shares of Omeros in a report on Tuesday. StockNews.com lowered Omeros from a “hold” rating to a “sell” rating in a research note on Wednesday, April 9th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $22.50.

Omeros Trading Up 0.5%

OMER stock opened at $3.95 on Friday. The company has a market cap of $230.31 million, a PE ratio of -1.71 and a beta of 2.42. The stock has a 50-day moving average price of $7.15 and a two-hundred day moving average price of $8.12. Omeros has a 12-month low of $3.00 and a 12-month high of $13.60.

Omeros (NASDAQ:OMER) last issued its earnings results on Monday, March 31st. The biopharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.08. During the same period in the previous year, the firm posted ($0.15) EPS. Equities analysts forecast that Omeros will post -3.09 EPS for the current fiscal year.

Hedge Funds Weigh In On Omeros

Institutional investors and hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. raised its stake in shares of Omeros by 3.0% in the 1st quarter. Vanguard Group Inc. now owns 3,237,256 shares of the biopharmaceutical company’s stock valued at $26,610,000 after purchasing an additional 95,599 shares in the last quarter. Nomura Holdings Inc. grew its stake in Omeros by 136.2% in the fourth quarter. Nomura Holdings Inc. now owns 747,281 shares of the biopharmaceutical company’s stock worth $7,383,000 after purchasing an additional 430,932 shares in the last quarter. Two Sigma Investments LP increased its holdings in Omeros by 8.8% in the fourth quarter. Two Sigma Investments LP now owns 162,991 shares of the biopharmaceutical company’s stock valued at $1,610,000 after buying an additional 13,201 shares during the last quarter. Bank of New York Mellon Corp raised its stake in Omeros by 2.2% during the first quarter. Bank of New York Mellon Corp now owns 151,062 shares of the biopharmaceutical company’s stock valued at $1,242,000 after buying an additional 3,321 shares in the last quarter. Finally, Susquehanna Fundamental Investments LLC bought a new position in Omeros during the 4th quarter worth approximately $1,488,000. 48.79% of the stock is currently owned by hedge funds and other institutional investors.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.